87 related articles for article (PubMed ID: 10923148)
1. [Use of angiotensin-II-antagonists in hypertension].
Birkenhäger WH; de Leeuw PW
Ned Tijdschr Geneeskd; 2000 Jul; 144(29):1397-402. PubMed ID: 10923148
[TBL] [Abstract][Full Text] [Related]
2. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Coca A; Giner V
Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
[TBL] [Abstract][Full Text] [Related]
3. The role of angiotensin II receptors and their antagonists in hypertension.
van Zwieten PA
Ann Ital Med Int; 2000; 15(1):85-91. PubMed ID: 10842896
[TBL] [Abstract][Full Text] [Related]
4. Update on the efficacy of angiotensin receptor blockers in treatment of hypertension.
Am J Manag Care; 2005 Nov; 11(13 Suppl):S386-91. PubMed ID: 16300453
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
Costantino S; Millozzi F; Scarlata S
Clin Ter; 2001; 152(2):77-8. PubMed ID: 11441526
[No Abstract] [Full Text] [Related]
6. [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
de Boer RA; van Veldhuisen DJ; Gans RO; Gansevoort RT
Ned Tijdschr Geneeskd; 2003 Jan; 147(3):96-9. PubMed ID: 12577767
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension.
Waeber B
Expert Rev Cardiovasc Ther; 2003 May; 1(1):43-50. PubMed ID: 15030296
[TBL] [Abstract][Full Text] [Related]
8. [Angiotensin II receptor antagonists. Clinically significant differences].
Ibsen H; Rasmussen S
Ugeskr Laeger; 1999 Sep; 161(38):5332-6. PubMed ID: 10536525
[No Abstract] [Full Text] [Related]
9. Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Clin Sci (Lond); 2000 Oct; 99(4):331-41. PubMed ID: 10995600
[TBL] [Abstract][Full Text] [Related]
10. Peripheral administration of AT1 receptor blockers and pressor responses to central angiotensin II and sodium.
Zhang J; Leenen FH
Can J Physiol Pharmacol; 2001 Oct; 79(10):861-7. PubMed ID: 11697745
[TBL] [Abstract][Full Text] [Related]
11. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-II receptor antagonists: their place in therapy.
Kirk JK
Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
[TBL] [Abstract][Full Text] [Related]
15. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure.
Reaux A; Iturrioz X; Vazeux G; Fournie-Zaluski MC; David C; Roques BP; Corvol P; Llorens-Cortes C
Biochem Soc Trans; 2000; 28(4):435-40. PubMed ID: 10961935
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic and pharmacodynamic aspects of angiotensin II antagonists. Focus on arterial hypertension].
da Silva PM
Rev Port Cardiol; 1998 Jun; 17(6):545-55. PubMed ID: 9677832
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
De Godoy MA; Rattan S
J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
[TBL] [Abstract][Full Text] [Related]
19. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
Carnovali M
Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
